Although there have been few studies about metformin in bladder cancer, analysis of reviews and published studies revealed that more than 40% of patients with urothelial carcinoma had a dysregulated PI3K/AKT/mTOR pathway [25–30]. Here, MTOR is linked to urinary bladder cancer.